相关实验视频

Updated: Jan 13, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

曼吉费林的抗糖尿病潜力:一种in-silico和in-vivo方法

Anna Vesnina^1,2, Violeta Le¹, Svetlana Ivanova^2,3

¹Laboratory of Natural Nutraceuticals Biotesting, Kemerovo State University, Kemerovo 650043, Russia.

|October 29, 2025

概括

预计可以预防糖尿病的曼吉费林在体内表现出促炎作用,而不是抗炎或低血糖活性. 需要进一步的研究来探索更低的剂量和潜在的治疗益处的生物可用性.

科学领域:

药理学药理学是指药理学的学科.
生物化学生化学
在体和体内研究的研究.

背景情况:

曼吉费林是一种植物化合物,根据in silico分析预测具有抗糖尿病特性.
已发表的数据表明,曼吉费林在预防糖尿病方面具有潜力.
这项研究旨在通过实证体内试验来验证这些预测.

研究的目的:

为了获得Mangiferin生物活性的体内证据,特别是其抗炎症,抗糖尿病和低胆固醇作用.
为了比较体内结果与in silico预测对mangiferin的抗糖化活性.
在动物模型中调查曼吉费林对炎症,葡萄糖水平和胆固醇的影响.

主要方法:

在使用IT Microcosm系统进行的in silico预测中,确定了mangiferin活动的潜在生物标 (MAPK10,HCAR2,CALCRL).
在Sprague-Dawley大鼠中评估了诱导急性和慢性炎症的体内抗炎活性.
在Sprague-Dawley大鼠和Mus musculus小鼠中分别评估了低血糖和低胆固醇活动,使用阿洛克桑诱导的糖尿病和Kolliphor P 407诱导的高胆固醇血症模型.

主要成果:

在体内研究表明,曼吉费林表现出抗炎活性.
曼吉费林在测试模型中没有显著影响空腹体重,血糖或血清胆固醇度.
经验发现与对抗糖尿病和抗炎性质的in silico预测相矛盾.

结论:

在mangiferin的in silico预测的生物活动和观察到的in vivo效应之间存在差异.
曼吉费林在本研究中表现出促炎,而不是抗炎或低血糖作用.
建议进行进一步的研究,重点是较低的曼吉费林剂量和提高其生物可用性的策略,以协调预测和实际活动.

关键词:

这种病名为Hedysarum neglectum.具有抗炎和抗糖尿病活性.在糖尿病中,糖尿病是血糖性糖尿病.在的中.在Mangiferin中进行调试.

更多相关视频

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...